Eli Lilly's Oral Drug Shows Promise in Lowering Genetic Cholesterol

Muvalaplin significantly reduces lipoprotein(a) levels, a major heart disease risk factor, in early trials.

Muvalaplin, an oral medication by Eli Lilly, reduced lipoprotein(a) levels by up to 86% in a Phase 2 trial.
Lipoprotein(a) is a genetic risk factor for cardiovascular diseases, affecting 1 in 5 people globally.
The trial involved 233 adults and showed no new safety concerns, with similar adverse events in both drug and placebo groups.
Current treatments for elevated lipoprotein(a) are injectable, making muvalaplin a novel oral alternative.
Further large-scale trials are needed to confirm if lowering lipoprotein(a) can reduce cardiovascular events.